Table 1.
Patients’ baseline characteristics
| PETAL n = 427 |
OPTIMAL>60 n = 503 |
Total n = 930 |
|
|---|---|---|---|
| Male | 235 (55%) | 290 (58%) | 525 (56%) |
| Female | 192 (45%) | 213 (42%) | 405 (44%) |
| Age, median (range) | 61* (18–80) | 71 (61–80) | 68 (18–80) |
| Age > 60 years | 214* (50%) | 503 (100%) | 717* (77%) |
| LDH > UNL | 247* (58%) | 255 (51%) | 502* (54%) |
| ECOG > 1 | 39* (9%) | 23 (5%) | 62* (7%) |
| Stage III/IV | 239* (56%) | 262 (52%) | 501* (54%) |
| Extralymphatic inv. > 1 | 130* (31%) | 151 (30%) | 281* (30%) |
| IPI 0, 1 | 166* (39%) | 140 (28%) | 306* (33%) |
| IPI 2 | 98* (23%) | 137 (27%) | 235* (25%) |
| IPI 3 | 98* (23%) | 138 (27%) | 236* (25%) |
| IPI 4, 5 | 64* (15%) | 88 (17%) | 152* (16%) |
| Bone marrow involvement by BMB | 36 (8%) | 49 (10%) | 85 (9%) |
| B-symptoms** | 133 (31%) | 106 (21%) | 239 (26%) |
| Reference pathology | |||
| DLBCL | 407 (95%) | 489 (97%) | 896 (96%) |
| PMBCL | 16 (4%) | 4 (1%) | 20 (2%) |
| Follicular lymphoma 3b | 4 (1%) | 10 (2%) | 14 (2%) |
| Bone marrow involvement by FDG PET/CT | 88 (21%) | 97 (19%) | 185 (20%) |
| Intensity of FDG uptake | |||
| Uptake moderately > liver | 4 (4%) | 5 (5%) | 9 (5%) |
| Uptake markedly increased > liver | 84 (96%) | 92 (95%) | 176 (95%) |
| Type of lesion in FDG PET/CT | |||
| Unifocal | 26 (30%) | 18 (19%) | 44 (24%) |
| Multifocal | 43 (49%) | 75 (77%) | 118 (64%) |
| Diffuse | 19 (22%) | 4 (4%) | 23 (12%) |
| Skeletal involvement | |||
| Osseous involvement | 40 (46%) | 63 (65%) | 103 (56%) |
| No osseous involvement | 38 (43%) | 32 (33%) | 70 (38%) |
| Unknown | 10 (11%) | 2 (2%) | 12 (6%) |
| BM localization in FDG PET/CT | |||
| Pelvis (dorsal) or sternum affected | 42 (48%) | 51 (53%) | 93 (50%) |
| Pelvis (dorsal) and sternum unaffected | 44 (50%) | 46 (47%) | 90 (49%) |
| Unknown | 2 (2%) | 0 (0%) | 2 (1%) |
| Bone marrow involvement by reference standard | 98 (23%) | 123 (24%) | 221 (24%) |
Abbreviations: BM, bone marrow; BMB, bone marrow biopsy; DLBCL, diffuse large B-cell lymphoma; ECOG, Eastern Cooperative Oncology Group performance status; FDG PET/CT, fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography; IPI, International Prognostic Index; LDH, lactate dehydrogenase; PMBCL, primary mediastinal B-cell lymphoma; ULN, upper limit of normal
*One patient with missing values for single IPI factors and IPI score
**9 (PETAL n = 1/OPTIMAL>60 n = 8) unknown values